Notice of Change to the Award Budget for PAR-18-303 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)

Notice Number: NOT-CA-19-062

Key Dates
Release Date: July 15, 2019

Related Announcements
PAR-18-303

Issued by
NATIONAL CANCER INSTITUTE (NCI)

Purpose

The purpose of this Notice is to revise the Award Budget Information for PAR-18-303 “Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)”.

This change will be effective immediately for the next due date, September 5, 2019.

Part 2. Section II. Award Information

Currently reads:

Award Budget
According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

Modified to Read (in italics):

Award Budget
Total funding support (direct costs, indirect costs, fee) normally may not exceed $252,131 for Phase I awards and $1,680,879 for Phase II awards. NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Navigate to the “Program Descriptions and Research Topics” document, Appendix A or the "2019 SBA approved topics list for budget waivers".

Each participating component may also set their own budget limit (higher or lower than the above) in the “Limited Amount of Award Section” of their respective topics section. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the hard caps listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Amir Rahbar, Ph.D., M.B.A.
National Cancer Institute (NCI)
Telephone: 240-276-5230
Email: rahbaram@mail.nih.gov